We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Artificial Sweetener on Gastrointestinal (GI) Peptide Secretion

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00978900
First Posted: September 17, 2009
Last Update Posted: September 17, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Hospital, Basel, Switzerland
  Purpose
The purpose of this study is to examine the influence of artificial sweeteners (aspartame, acesulfame K, sucralose) and carbohydrate sugars (glucose, fructose) on the release of gastrointestinal satiety hormones in humans.

Condition Intervention Phase
Healthy Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars Dietary Supplement: Water Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Carbohydrates and Non Caloric Sweeteners: Differential Effects on Appetite and Secretion of Gastrointestinal Satiety Peptide

Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • Gastrointestinal peptide secretion [ Time Frame: 2 hour blood sampling ]

Enrollment: 12
Study Start Date: December 2008
Study Completion Date: July 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Acesulfame K Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Active Comparator: Sucralose Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Active Comparator: Aspartame Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Active Comparator: Glucose Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Active Comparator: Fructose Dietary Supplement: Artificial sweeteners; Carbohydrate Sugars
sweetening agent dissolved in tap water, administered via intragastric tube
Placebo Comparator: Water Dietary Supplement: Water

Detailed Description:
Artificial Sweeteners significantly lower energy density of foods and beverages. They are used by diabetics as sugar substitutes as well as by consumers as aids for dietary control. Despite numerous studies which show mainly no influence of artificial sweeteners on glucose metabolism and food intake, discrepancies consist about the real effects of artificial sweeteners. Studies by Blundell and Hill in 1986 have however shown that the consumption of artificial sweeteners resulted in an increase of appetite ratings; the efficiency of AS has therefore been questioned. With respect to the world wide increase in the prevalence in obesity, it seems important to clarify whether artificial sweeteners can help regulate body weight or not. This study will explore the effect of artificial sweeteners on the release of the gastrointestinal satiety hormones PYY, GLP-1, GIP and ghrelin.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subject with a body-mass index of 19.0-24.5
  • Normal eating habits
  • Age 18-40 years
  • Stable body weight for at least three months

Exclusion Criteria:

  • Smoking
  • Substance abuse
  • Regular intake of medications (except for oral contraceptives)
  • Medical or psychiatric illness
  • history of gastrointestinal disorders
  • food allergies
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00978900


Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Principal Investigator: Christoph Beglinger, MD Clinical Research Center, University Hospital Basel
  More Information

Responsible Party: Beglinger Christoph, Prof. Dr. med., Department of Gastroenterology, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00978900     History of Changes
Other Study ID Numbers: EKBB 69/04
First Submitted: September 16, 2009
First Posted: September 17, 2009
Last Update Posted: September 17, 2009
Last Verified: September 2009

Keywords provided by University Hospital, Basel, Switzerland:
satiety peptides
GLP-1
PYY
ghrelin
appetite profile
Sweetening Agents